You are not logged in.

Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients

Boon, H., Bosselaar, M., Praet, S., Blaak, E.E., Saris, W.H.M., Wagenmakers, A.J.M., McGee, Sean L., Tack, C.J., Smits, P., Hargreaves, Mark and van Loon, L.J.C. 2008, Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients, Diabetologia, vol. 51, no. 10, pp. 1893-1900, doi: 10.1007/s00125-008-1108-7.

Attached Files
Name Description MIMEType Size Downloads

Title Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients
Author(s) Boon, H.
Bosselaar, M.
Praet, S.
Blaak, E.E.
Saris, W.H.M.
Wagenmakers, A.J.M.
McGee, Sean L.ORCID iD for McGee, Sean L.
Tack, C.J.
Smits, P.
Hargreaves, Mark
van Loon, L.J.C.
Journal name Diabetologia
Volume number 51
Issue number 10
Start page 1893
End page 1900
Total pages 8
Publisher Springer
Place of publication Heidelberg, Germany
Publication date 2008-10
ISSN 0012-186X
Summary Aims/hypothesis: The 5′-AMP-activated protein kinase (AMPK) pathway is intact in type 2 diabetic patients and is seen as a target for diabetes treatment. In this study, we aimed to assess the impact of the AMPK activator 5-aminoimidazole-4-carboxamide riboside (AICAR) on both glucose and fatty acid metabolism in vivo in type 2 diabetic patients.

Methods: Stable isotope methodology and blood and muscle biopsy sampling were applied to assess blood glucose and fatty acid kinetics following continuous i.v. infusion of AICAR (0.75 mg kg−1 min−1) and/or NaCl (0.9%) in ten male type 2 diabetic patients (age 64 ± 2 years; BMI 28 ± 1 kg/m2).
Results Plasma glucose rate of appearance (R a) was reduced following AICAR administration, while plasma glucose rate of disappearance (R d) was similar in the AICAR and control test. Consequently, blood glucose disposal (R d expressed as a percentage of R a) was increased following AICAR infusion (p < 0.001). Accordingly, a greater decline in plasma glucose concentration was observed following AICAR infusion (p < 0.001). Plasma NEFA R a and R d were both significantly reduced in response to AICAR infusion, and were accompanied by a significant decline in plasma NEFA concentration. Although AMPK phosphorylation in skeletal muscle was not increased, we observed a significant increase in acetyl-CoA carboxylase phosphorylation (p < 0.001).

: The i.v. administration of AICAR reduces hepatic glucose output, thereby lowering blood glucose concentrations in vivo in type 2 diabetic patients. Furthermore, AICAR administration stimulates hepatic fatty acid oxidation and/or inhibits whole body lipolysis, thereby reducing plasma NEFA concentration.
Language eng
DOI 10.1007/s00125-008-1108-7
Field of Research 060114 Systems Biology
Socio Economic Objective 970106 Expanding Knowledge in the Biological Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2008, Springer
Persistent URL

Document type: Journal Article
Collection: School of Medicine
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 62 times in TR Web of Science
Scopus Citation Count Cited 68 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 618 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Fri, 12 Mar 2010, 11:49:02 EST by Sean McGee

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact